Literature DB >> 10322876

[Treatment of severe cholestatic hepatitis by integrated traditional Chinese and Western medicine].

J P He1, C B Wang.   

Abstract

OBJECTIVE: To study the curative effect of Chinese medicine in treating severe cholestatic-hepatitis (SCH).
METHODS: Three hundred and fifty patients of SCH with total bilirubin level > or = 171 mumol/L were treated with Chinese medicines. For those with Blood Stasis Syndrome, treated with the recipe mainly consisted of Radix Paeoniae Rubra, and for which accompanied with blood Heat, fluid retention in epigastric region. Dampness dissenubated in Sanjiao ([symbol: see text]) or both Spleen and Kidney Yang-Deficiency Syndrome, the recipe was used in modification according to the Syndrome.
RESULTS: Treatment was markedly effective in 288 cases and effective in 26 cases, the total effective rate being 89.7%.
CONCLUSION: It is difficult in treating severe cholestatic hepatitis, especially the chronic cholestatic hepatitis, which could develop to severe chronic hepatitis if the jaundice lasted for a long time. This study showed a good effect of Chinese herbal medicine in eliminating jaundice.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 10322876

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  2 in total

1.  Large dose means significant effect--dose and effect relationship of Chi-Dan-Tui-Huang decoction on alpha-naphthylisothiocyanate-induced cholestatic hepatitis in rats.

Authors:  Yanling Zhao; Xiao Ma; Jiabo Wang; Ruiqing Wen; Lei Jia; Yun Zhu; Ruisheng Li; Ruilin Wang; Jianyu Li; Lifu Wang; Yonggang Li; Xiaohe Xiao
Journal:  BMC Complement Altern Med       Date:  2015-04-02       Impact factor: 3.659

2.  Mechanism of Paeoniflorin in the Treatment of Bile Duct Ligation-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology.

Authors:  Shizhang Wei; Xiao Ma; Ming Niu; Ruilin Wang; Tao Yang; Dan Wang; Jianxia Wen; Haotian Li; Yanling Zhao
Journal:  Front Pharmacol       Date:  2020-10-20       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.